1. Signaling Pathways
  2. Cell Cycle/DNA Damage
  3. LIM Kinase (LIMK)
  4. LIMK2 Isoform
  5. LIMK2 Inhibitor

LIMK2 Inhibitor

LIMK2 Inhibitors (8):

Cat. No. Product Name Effect Purity
  • HY-18305
    BMS-5
    Inhibitor 99.51%
    BMS-5 (LIMKi 3) is a potent LIMK inhibitor with IC50s of 7 nM and 8 nM for LIMK1 and LIMK2, respectively.
  • HY-122630
    TH-257
    Inhibitor 98.01%
    TH-257 is a potent inhibitor of LIMK1 and LIMK2 with IC50 values of 84 nM and 39 nM for LIMK1 and LIMK2, respectively, and it can be used as a chemical probe for LIMK1 and LIMK2. TH-257 is an allosteric inhibitor targeting a binding pocket induced by an αC and DFG-out conformation. TH257 is exquisitely selective and no significant activity against the wider kinome has been observed in the KINOMEscan assay at 1 μM.
  • HY-18304
    BMS-3
    Inhibitor 99.46%
    BMS-3 is a potent LIMK inhibitor with IC50s of 5 nM and 6 nM for LIMK1 and LIMK2, respectively.
  • HY-19352
    T56-LIMKi
    Inhibitor 99.07%
    T56-LIMKi is a selective inhibitor of LIMK2; inhibits the growth of Panc-1 cells with an IC50 of 35.2 μM.
  • HY-151539
    TH470
    Inhibitor 99.57%
    TH470 is a highly selective LIMK1/2 (LIM kinase1/2) inhibitor (LIMK1 IC50=9.8 nM; LIMK2 IC50=13 nM), and can be used in orphan disease research.
  • HY-120025
    CRT0105950
    Inhibitor 99.91%
    CRT0105950 is a potent LIMK inhibitor, with IC50s of 0.3 nM and 1 nM for LIMK1 and LIMK2 respectively. CRT0105950 can be used for the research of cancer.
  • HY-128062
    LIMK1 inhibitor BMS-4
    Inhibitor ≥99.0%
    LIMK1 inhibitor BMS-4 is a LIM Kinase (LIMK) inhibitor targeting to LIMK1/2. LIMK1 inhibitor BMS-4 inhibits phosphorylation of cofilin, the LIMK substrate. However, LIMK1 inhibitor BMS-4 is noncytotoxic on A549 cells.
  • HY-14227
    LIMK-IN-1
    Inhibitor
    LIMK-IN-1 (Compound 14) is an inhibitor of LIM-Kinase (LIMK), with IC50s of 0.5 nM and 0.9 nM for LIMK1 and LIMK2, respectively. LIMK-IN-1 can be used for ocular hypertension and associated glaucoma research.